Sylvia Franc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sylvia Franc has a total of 375 co-authors. Here are the top co-authors by number of shared publications:
G. Charpentier
CERITD-BIOPARC GENOPOLE Evry, Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France
19 shared publicationsGuillaume Charpentier
CERITD, French Center for Studies and Research on the Intensification of Diabetes Treatment, F-91000 Evry, France, and LBEPS Laboratory of Exercise Biology for Performance and Health, Evry University, Evry-Courcouronnes, France; Department of Diabetes and endocrinology, Sud-Francilien Hospital, Corbeil Essonnes, France
16 shared publications- Pierre-Yves Benhamou
Department of Endocrinology Grenoble University Hospital, Grenoble Alpes University, INSERM U1055, LBFA Grenoble France
12 shared publications A. Daoudi
CERITD, Évry, France
8 shared publicationsD. Dardari
Centre hospitalier sud Francilien, Corbeil-Essonnes, France
7 shared publicationsA. Penfornis
Department of Diabetes and Endocrinology, Lariboisière Hospital, University Paris 7, AP-HP, 75475 Paris, France
6 shared publications
Latest Publications
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Insulinothérapie en boucle fermée chez le sujet atteint de diabète de type 1 : efficacité en vie réelle pour réduire l'incidence des hypoglycémies liées à l'activité physique
Introduction. Le système d’insulinothérapie en boucle fermée (BF) est un dispositif médical qui automatise l’administration d'insuline en fonction de la glycémie, à l’image du pancréas humain. Si les dispositifs actuels de BF contrôlent très bien la glycémie la nuit et à jeun, ils restent en difficulté pour contrôler les éléments perturbateurs que sont l’alimentation et l’activité physique (AP), et ceux-ci doivent être déclarés de façon anticipée (BF hybride). Si la gestion des repas est bien avancée, beaucoup d’aspects liés à l’AP restent à approfondir. L'AP régulière est bénéfique pour les patients atteints de diabète de type 1 (DT1), car elle réduit leur risque cardiovasculaire, améliore globalement leur contrôle glycémique (réduction de HbA1c et des besoins en insuline), et améliore leur bien-être. Cependant, la peur de l'hypoglycémie est un obstacle majeur qui limite leur pratique d’AP. Objectifs. Ce travail poursuit un triple objectif : (i) démontrer l’efficacité et la tolérance du système d’insulinothérapie en BF DBLG1 pour assurer le contrôle glycémique du sujet atteint de DT1, (ii) évaluer l’efficacité de ce système pour prévenir les hypoglycémies induites par l'AP, et (iii) déterminer les facteurs explicatifs d’une éventuelle efficacité thérapeutique. Contribution personnelle. Deux études en conditions de vie réelle ont démontré que le système d'insulinothérapie en BF DBLG1 augmente significativement le temps dans la cible glycémique par rapport à la thérapie standard (boucle ouverte). Deux autres études en vie réelle ont montré la réduction de l’incidence des hypoglycémies liées à l’AP par le système DBLG1. Des ajustements des doses d'insuline et la recommandation d'un apport préventif en glucides expliquent probablement ce bénéfice thérapeutique. Limitations de la BF. Bien qu’automatisés, les systèmes d'insulinothérapie en BF nécessitent encore que l'utilisateur déclare la teneur en glucides de ses repas et son AP pour ajuster efficacement l’administration d'insuline. Perspectives. Plusieurs travaux en cours sont consacrés au développement de systèmes en BF implémentant détection et gestion entièrement automatisées de l’AP et des repas. Conclusions. Le nouveau système d'insulinothérapie en BF DBLG1 réduit notablement l'hypoglycémie induite par l'AP, en ajustant l'administration d’insuline et en recommandant un apport préventif en glucides.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Insulinothérapie en boucle fermée chez le sujet atteint de diabète de type 1 : efficacité en vie réelle pour réduire l'incidence des hypoglycémies liées à l'activité physique
Introduction. Le système d’insulinothérapie en boucle fermée (BF) est un dispositif médical qui automatise l’administration d'insuline en fonction de la glycémie, à l’image du pancréas humain. Si les dispositifs actuels de BF contrôlent très bien la glycémie la nuit et à jeun, ils restent en difficulté pour contrôler les éléments perturbateurs que sont l’alimentation et l’activité physique (AP), et ceux-ci doivent être déclarés de façon anticipée (BF hybride). Si la gestion des repas est bien avancée, beaucoup d’aspects liés à l’AP restent à approfondir. L'AP régulière est bénéfique pour les patients atteints de diabète de type 1 (DT1), car elle réduit leur risque cardiovasculaire, améliore globalement leur contrôle glycémique (réduction de HbA1c et des besoins en insuline), et améliore leur bien-être. Cependant, la peur de l'hypoglycémie est un obstacle majeur qui limite leur pratique d’AP. Objectifs. Ce travail poursuit un triple objectif : (i) démontrer l’efficacité et la tolérance du système d’insulinothérapie en BF DBLG1 pour assurer le contrôle glycémique du sujet atteint de DT1, (ii) évaluer l’efficacité de ce système pour prévenir les hypoglycémies induites par l'AP, et (iii) déterminer les facteurs explicatifs d’une éventuelle efficacité thérapeutique. Contribution personnelle. Deux études en conditions de vie réelle ont démontré que le système d'insulinothérapie en BF DBLG1 augmente significativement le temps dans la cible glycémique par rapport à la thérapie standard (boucle ouverte). Deux autres études en vie réelle ont montré la réduction de l’incidence des hypoglycémies liées à l’AP par le système DBLG1. Des ajustements des doses d'insuline et la recommandation d'un apport préventif en glucides expliquent probablement ce bénéfice thérapeutique. Limitations de la BF. Bien qu’automatisés, les systèmes d'insulinothérapie en BF nécessitent encore que l'utilisateur déclare la teneur en glucides de ses repas et son AP pour ajuster efficacement l’administration d'insuline. Perspectives. Plusieurs travaux en cours sont consacrés au développement de systèmes en BF implémentant détection et gestion entièrement automatisées de l’AP et des repas. Conclusions. Le nouveau système d'insulinothérapie en BF DBLG1 réduit notablement l'hypoglycémie induite par l'AP, en ajustant l'administration d’insuline et en recommandant un apport préventif en glucides.
- 26 December 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (4) , 959-968
Safety and glycemic outcomes of DBLG1 coupled to the DANA-i pump in adults and adolescents with type 1 diabetes mellitus. The SP8 trial
Purpose DBLG1 is a hybrid closed-loop (CL) system interoperable with ViCentra Kaleido and Roche Insight pumps. The SP8 trial investigated the safety and glycemic outcomes of DBLG1 coupled to the DANA-i pump (DBLG1-DANAi) in adults and adolescents with type 1 diabetes mellitus (T1D). Methods The safety of DBLG1-DANAi (primary outcome of SP8) was evaluated using two criteria: (i) the incidence of serious adverse device events (SADEs) and (ii) the time spent in hypoglycemia (time below range 70 mg/dL [3.9 mmol/L], TBR70) with DBLG1-DANAi compared to an SAP (sensor-augmented pump) system. Secondary outcomes included non-serious adverse events and standard glycemic metrics. Five months after its start, the trial was halted due to the COVID-19 crisis. One hundred and forty (140) of the 148 planned adults had already been included in the study, as well as all planned adolescents (N = 36). Results The intention-to-treat (ITT) population included 105 adult and 36 adolescent participants in whom no SADE was observed with DBLG1-DANAi. The per-protocol (PP) population consisted of 73 adults and 18 adolescents who spent two weeks with SAP, followed by two weeks with DBLG1-DANAi. No increase in TBR70 was observed during the DBLG1-DANAi period. Furthermore, the time spent in the glucose level range of 70–180 mg/dL [3.9–10.0 mmol/L] (time in range, TIR70-180) increased significantly with DBLG1-DANAi, both in adults (+ 10.5%; p < 0.0001) and adolescents (+ 16.0%; p < 0.0001). Conclusion During the two-week study period, DBLG1 was interoperable with the DANA-i pump. This result requires confirmation in future long-term studies. ClinicalTrials.gov ID NCT04190277
- 26 December 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (4) , 959-968
Safety and glycemic outcomes of DBLG1 coupled to the DANA-i pump in adults and adolescents with type 1 diabetes mellitus. The SP8 trial
Purpose DBLG1 is a hybrid closed-loop (CL) system interoperable with ViCentra Kaleido and Roche Insight pumps. The SP8 trial investigated the safety and glycemic outcomes of DBLG1 coupled to the DANA-i pump (DBLG1-DANAi) in adults and adolescents with type 1 diabetes mellitus (T1D). Methods The safety of DBLG1-DANAi (primary outcome of SP8) was evaluated using two criteria: (i) the incidence of serious adverse device events (SADEs) and (ii) the time spent in hypoglycemia (time below range 70 mg/dL [3.9 mmol/L], TBR70) with DBLG1-DANAi compared to an SAP (sensor-augmented pump) system. Secondary outcomes included non-serious adverse events and standard glycemic metrics. Five months after its start, the trial was halted due to the COVID-19 crisis. One hundred and forty (140) of the 148 planned adults had already been included in the study, as well as all planned adolescents (N = 36). Results The intention-to-treat (ITT) population included 105 adult and 36 adolescent participants in whom no SADE was observed with DBLG1-DANAi. The per-protocol (PP) population consisted of 73 adults and 18 adolescents who spent two weeks with SAP, followed by two weeks with DBLG1-DANAi. No increase in TBR70 was observed during the DBLG1-DANAi period. Furthermore, the time spent in the glucose level range of 70–180 mg/dL [3.9–10.0 mmol/L] (time in range, TIR70-180) increased significantly with DBLG1-DANAi, both in adults (+ 10.5%; p < 0.0001) and adolescents (+ 16.0%; p < 0.0001). Conclusion During the two-week study period, DBLG1 was interoperable with the DANA-i pump. This result requires confirmation in future long-term studies. ClinicalTrials.gov ID NCT04190277
- Open Access
- 25 June 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (9) , 4662-4673
Emotional distress as a therapeutic target against persistent poor glycaemic control in subjects with type 1 diabetes: A systematic review
Persistent poor glycaemic control is frequently observed in subjects with type 1 diabetes (T1D). The burden of diabetes self‐management, fear of hypoglycaemia, and other diabetes‐specific stressors are associated with diabetes distress and poor glycaemic control. However, psychological interventions to reduce diabetes distress have only benefited certain groups of patients. Psychosocial stressors (unemployment, financial problems) can lead to psychosocial distress and persistent poor glycaemic control in subjects with T1D. Therefore, diabetes distress and psychosocial distress can cause a similar state of ‘emotional distress’. Here we conducted a systematic review of emotional distress and persistent poor glycaemic control in subjects with T1D. A total of 108 articles were identified in bibliographic databases (PubMed, Google Scholar, ScienceDirect, PsycNet APA, ERIC, EMBASE and Cochrane) and other literature sources. Of these, 24 articles were included in the analysis. As expected, diabetes stressors have been found to combine with psychosocial stressors to produce emotional distress and worsen glycaemic control. Psychological resilience and positive life events reduced the impact of emotional distress on glycaemic control. The EMBARK trial demonstrated the efficacy of an emotion‐focused approach in achieving clinically significant long‐term improvement in glycaemic control. In conclusion, emotional distress could be a new therapeutic target against persistent poor glycaemic control. This hypothesis could be tested in intervention trials including: (i) diabetes distress and psychosocial distress as main outcome measures, (ii) positive life events as a secondary outcome measure, and (iii) psychological resilience among the baseline characteristics of study participants.
- 25 June 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (9) , 4662-4673
Open AccessEmotional distress as a therapeutic target against persistent poor glycaemic control in subjects with type 1 diabetes: A systematic review
Persistent poor glycaemic control is frequently observed in subjects with type 1 diabetes (T1D). The burden of diabetes self‐management, fear of hypoglycaemia, and other diabetes‐specific stressors are associated with diabetes distress and poor glycaemic control. However, psychological interventions to reduce diabetes distress have only benefited certain groups of patients. Psychosocial stressors (unemployment, financial problems) can lead to psychosocial distress and persistent poor glycaemic control in subjects with T1D. Therefore, diabetes distress and psychosocial distress can cause a similar state of ‘emotional distress’. Here we conducted a systematic review of emotional distress and persistent poor glycaemic control in subjects with T1D. A total of 108 articles were identified in bibliographic databases (PubMed, Google Scholar, ScienceDirect, PsycNet APA, ERIC, EMBASE and Cochrane) and other literature sources. Of these, 24 articles were included in the analysis. As expected, diabetes stressors have been found to combine with psychosocial stressors to produce emotional distress and worsen glycaemic control. Psychological resilience and positive life events reduced the impact of emotional distress on glycaemic control. The EMBARK trial demonstrated the efficacy of an emotion‐focused approach in achieving clinically significant long‐term improvement in glycaemic control. In conclusion, emotional distress could be a new therapeutic target against persistent poor glycaemic control. This hypothesis could be tested in intervention trials including: (i) diabetes distress and psychosocial distress as main outcome measures, (ii) positive life events as a secondary outcome measure, and (iii) psychological resilience among the baseline characteristics of study participants.
- Open Access
- 8 November 2024
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 26 (11) , 814-822
Expert Panel Recommendations for a Standardized Ambulatory Glucose Profile Report for Connected Insulin Pens
Background: : Connected insulin pens capture data on insulin dosing/timing and can integrate with continuous glucose monitoring (CGM) devices with essential insulin and glucose metrics combined into a single platform. Standardization of connected insulin pen reports is desirable to enhance clinical utility with a single report. Methods: : An international expert panel was convened to develop a standardized connected insulin pen report incorporating insulin and glucose metrics into a single report containing clinically useful information. An extensive literature review and identification of examples of current connected insulin pen reports were performed serving as the basis for creation of a draft of a standardized connected insulin pen report. The expert panel participated in three virtual standardization meetings and online surveys. Results: : The Ambulatory Glucose Profile (AGP) Report: Connected Insulin Pen brings all clinically relevant CGM-derived glucose and connected insulin pen metrics into a single simplified two-page report. The first page contains the time in ranges bar, summary of key insulin and glucose metrics, the AGP curve, and detailed basal (long-acting) insulin assessment. The second page contains the bolus (mealtime and correction) insulin assessment periods with information on meal timing, insulin-to-carbohydrate ratio, average bolus insulin dose, and number of days with bolus doses recorded. The report’s second page contains daily glucose profiles with an overlay of the timing and amount of basal and bolus insulin administered. Conclusion: : The AGP Report: Connected Insulin Pen is a standardized clinically useful report that should be considered by companies developing connected pen technology as part of their system reporting/output.
- 8 November 2024
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 26 (11) , 814-822
Open AccessExpert Panel Recommendations for a Standardized Ambulatory Glucose Profile Report for Connected Insulin Pens
Background: : Connected insulin pens capture data on insulin dosing/timing and can integrate with continuous glucose monitoring (CGM) devices with essential insulin and glucose metrics combined into a single platform. Standardization of connected insulin pen reports is desirable to enhance clinical utility with a single report. Methods: : An international expert panel was convened to develop a standardized connected insulin pen report incorporating insulin and glucose metrics into a single report containing clinically useful information. An extensive literature review and identification of examples of current connected insulin pen reports were performed serving as the basis for creation of a draft of a standardized connected insulin pen report. The expert panel participated in three virtual standardization meetings and online surveys. Results: : The Ambulatory Glucose Profile (AGP) Report: Connected Insulin Pen brings all clinically relevant CGM-derived glucose and connected insulin pen metrics into a single simplified two-page report. The first page contains the time in ranges bar, summary of key insulin and glucose metrics, the AGP curve, and detailed basal (long-acting) insulin assessment. The second page contains the bolus (mealtime and correction) insulin assessment periods with information on meal timing, insulin-to-carbohydrate ratio, average bolus insulin dose, and number of days with bolus doses recorded. The report’s second page contains daily glucose profiles with an overlay of the timing and amount of basal and bolus insulin administered. Conclusion: : The AGP Report: Connected Insulin Pen is a standardized clinically useful report that should be considered by companies developing connected pen technology as part of their system reporting/output.
- Open Access
- 5 December 2023
- Published by Springer Nature in Diabetologia
- Vol. 67 (2) , 327-332
Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk and identify a subgroup of patients sensitive to sulfonylureas
Aims/hypothesis: GLIS3 encodes a transcription factor involved in pancreatic beta cell development and function. Rare pathogenic, bi-allelic mutations in GLIS3 cause syndromic neonatal diabetes whereas frequent SNPs at this locus associate with common type 2 diabetes risk. Because rare, functional variants located in other susceptibility genes for type 2 diabetes have already been shown to strongly increase individual risk for common type 2 diabetes, we aimed to investigate the contribution of rare pathogenic GLIS3 variants to type 2 diabetes. Methods: GLIS3 was sequenced in 5471 individuals from the Rare Variants Involved in Diabetes and Obesity (RaDiO) study. Variant pathogenicity was assessed following the criteria established by the American College of Medical Genetics and Genomics (ACMG). To address the pathogenic strong criterion number 3 (PS3), we conducted functional investigations of these variants using luciferase assays, focusing on capacity of GLIS family zinc finger 3 (GLIS3) to bind to and activate the INS promoter. The association between rare pathogenic or likely pathogenic (P/LP) variants and type 2 diabetes risk (and other metabolic traits) was then evaluated. A meta-analysis combining association results from RaDiO, the 52K study (43,125 individuals) and the TOPMed study (44,083 individuals) was finally performed. Results: Through targeted resequencing of GLIS3, we identified 105 rare variants that were carried by 395 participants from RaDiO. Among them, 49 variants decreased the activation of the INS promoter. Following ACMG criteria, 18 rare variants were classified as P/LP, showing an enrichment in the last two exons compared with the remaining exons (p3.5). The burden of these P/LP variants was strongly higher in individuals with type 2 diabetes (p=3.0×10−3; OR 3.9 [95% CI 1.4, 12]), whereas adiposity, age at type 2 diabetes diagnosis and cholesterol levels were similar between variant carriers and non-carriers with type 2 diabetes. Interestingly, all carriers with type 2 diabetes were sensitive to oral sulfonylureas. A total of 7 P/LP variants were identified in both 52K and TOPMed studies. The meta-analysis of association studies obtained from RaDiO, 52K and TOPMed showed an enrichment of P/LP GLIS3 variants in individuals with type 2 diabetes (p=5.6×10−5; OR 2.1 [95% CI 1.4, 2.9]). Conclusions/interpretation: Rare P/LP GLIS3 variants do contribute to type 2 diabetes risk. The variants located in the distal part of the protein could have a direct effect on its functional activity by impacting its transactivation domain, by homology with the mouse GLIS3 protein. Furthermore, rare P/LP GLIS3 variants seem to have a direct clinical effect on beta cell function, which could be improved by increasing insulin secretion via the use of sulfonylureas. Graphical
- 5 December 2023
- Published by Springer Nature in Diabetologia
- Vol. 67 (2) , 327-332
Open AccessPathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk and identify a subgroup of patients sensitive to sulfonylureas
Aims/hypothesis: GLIS3 encodes a transcription factor involved in pancreatic beta cell development and function. Rare pathogenic, bi-allelic mutations in GLIS3 cause syndromic neonatal diabetes whereas frequent SNPs at this locus associate with common type 2 diabetes risk. Because rare, functional variants located in other susceptibility genes for type 2 diabetes have already been shown to strongly increase individual risk for common type 2 diabetes, we aimed to investigate the contribution of rare pathogenic GLIS3 variants to type 2 diabetes. Methods: GLIS3 was sequenced in 5471 individuals from the Rare Variants Involved in Diabetes and Obesity (RaDiO) study. Variant pathogenicity was assessed following the criteria established by the American College of Medical Genetics and Genomics (ACMG). To address the pathogenic strong criterion number 3 (PS3), we conducted functional investigations of these variants using luciferase assays, focusing on capacity of GLIS family zinc finger 3 (GLIS3) to bind to and activate the INS promoter. The association between rare pathogenic or likely pathogenic (P/LP) variants and type 2 diabetes risk (and other metabolic traits) was then evaluated. A meta-analysis combining association results from RaDiO, the 52K study (43,125 individuals) and the TOPMed study (44,083 individuals) was finally performed. Results: Through targeted resequencing of GLIS3, we identified 105 rare variants that were carried by 395 participants from RaDiO. Among them, 49 variants decreased the activation of the INS promoter. Following ACMG criteria, 18 rare variants were classified as P/LP, showing an enrichment in the last two exons compared with the remaining exons (p3.5). The burden of these P/LP variants was strongly higher in individuals with type 2 diabetes (p=3.0×10−3; OR 3.9 [95% CI 1.4, 12]), whereas adiposity, age at type 2 diabetes diagnosis and cholesterol levels were similar between variant carriers and non-carriers with type 2 diabetes. Interestingly, all carriers with type 2 diabetes were sensitive to oral sulfonylureas. A total of 7 P/LP variants were identified in both 52K and TOPMed studies. The meta-analysis of association studies obtained from RaDiO, 52K and TOPMed showed an enrichment of P/LP GLIS3 variants in individuals with type 2 diabetes (p=5.6×10−5; OR 2.1 [95% CI 1.4, 2.9]). Conclusions/interpretation: Rare P/LP GLIS3 variants do contribute to type 2 diabetes risk. The variants located in the distal part of the protein could have a direct effect on its functional activity by impacting its transactivation domain, by homology with the mouse GLIS3 protein. Furthermore, rare P/LP GLIS3 variants seem to have a direct clinical effect on beta cell function, which could be improved by increasing insulin secretion via the use of sulfonylureas. Graphical
- Open Access
- 21 February 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (6) , 1607-1613
One‐year real‐world performance of the DBLG1 closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany
Aim: The Diabeloop Generation 1 (DBLG1) system is an interoperable hybrid closed‐loop solution that was commercialized in Germany in March 2021. We report the longitudinal glycaemic outcomes among the first 3706 users in a real‐world setting. Methods: We performed a retrospective data collection of all consenting adult patients with type 1 diabetes who were equipped in Germany with the DBLG1 system before 30 April 2022, and with a minimum 14 days of closed‐loop usage. Results: In total, 3706 users (41% women, age 45.1 ± 14.5 years) met the inclusion criteria, reaching a mean follow‐up of 131.0 ± 85.1 days, an overall 485 600 days of continuous glucose monitoring data, and a median time spent in closed‐loop of 95.0% (IQR 89.1‐97.4). The median percentage time in range (70‐180 mg/dl) was 72.1% (IQR 65.0‐78.9); the time below 70 mg/dl was 0.9% (0.5‐1.7), the time below 54 mg/dl was 0.1% (0.1‐0.3), and the median Glucose Management Index was 7.0% (6.8‐7.3). Exploratory analysis of a subset of 2460 patients in whom baseline glycated haemoglobin (HbA1c) was available [7.4% (IQR 6.9‐8.0)] showed that the achieved mean time in range was influenced by baseline HbA1c, ranging from 65.8 ± 9.9% (A1c ≥8.5%) to 81.3 ± 6.8% (A1c <6.5%). Conclusion: This large real‐world analysis confirms the relevance of the DBLG1 automated insulin delivery solution for the achievement of standards of care in adult patients with type 1 diabetes.
- 21 February 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (6) , 1607-1613
Open AccessOne‐year real‐world performance of the DBLG1 closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany
Aim: The Diabeloop Generation 1 (DBLG1) system is an interoperable hybrid closed‐loop solution that was commercialized in Germany in March 2021. We report the longitudinal glycaemic outcomes among the first 3706 users in a real‐world setting. Methods: We performed a retrospective data collection of all consenting adult patients with type 1 diabetes who were equipped in Germany with the DBLG1 system before 30 April 2022, and with a minimum 14 days of closed‐loop usage. Results: In total, 3706 users (41% women, age 45.1 ± 14.5 years) met the inclusion criteria, reaching a mean follow‐up of 131.0 ± 85.1 days, an overall 485 600 days of continuous glucose monitoring data, and a median time spent in closed‐loop of 95.0% (IQR 89.1‐97.4). The median percentage time in range (70‐180 mg/dl) was 72.1% (IQR 65.0‐78.9); the time below 70 mg/dl was 0.9% (0.5‐1.7), the time below 54 mg/dl was 0.1% (0.1‐0.3), and the median Glucose Management Index was 7.0% (6.8‐7.3). Exploratory analysis of a subset of 2460 patients in whom baseline glycated haemoglobin (HbA1c) was available [7.4% (IQR 6.9‐8.0)] showed that the achieved mean time in range was influenced by baseline HbA1c, ranging from 65.8 ± 9.9% (A1c ≥8.5%) to 81.3 ± 6.8% (A1c <6.5%). Conclusion: This large real‐world analysis confirms the relevance of the DBLG1 automated insulin delivery solution for the achievement of standards of care in adult patients with type 1 diabetes.
- 31 January 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (5) , 956-961
The beneficial effects of closed‐loop insulin delivery in patients with highly unstable type 1 diabetes eligible for islet transplantation are maintained over 6 months: An extension study of the DBLHU‐WP10 trial
- 31 January 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (5) , 956-961
The beneficial effects of closed‐loop insulin delivery in patients with highly unstable type 1 diabetes eligible for islet transplantation are maintained over 6 months: An extension study of the DBLHU‐WP10 trial
- Open Access
- 19 May 2021
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (9) , 2170-2176
No more hypoglycaemia on days with physical activity and unrestricted diet when using a closed‐loop system for 12 weeks: A post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial
A post hoc analysis of the Diabeloop WP7 multicentre, randomized controlled trial was performed to investigate the efficacy of the Diabeloop Generation‐1 (DBLG1) closed‐loop system in controlling the hypoglycaemia induced by physical activity (PA) in real‐life conditions. Glycaemic outcomes were compared between days with and without PA in 56 patients with type 1 diabetes (T1D) using DBLG1 for 12 weeks. After the patient announces a PA, DBLG1 reduces insulin delivery and, if necessary, calculates the amount of preventive carbohydrates (CHO). Daily time spent in the interstitial glucose range less than 70 mg/dL was not significantly different between days with and without PA (2.0% ± 1.5% vs. 2.2% ± 1.1%), regardless of the intensity or duration of the PA. Preventive CHO intake recommended by the system was significantly higher in days with PA (41.1 ± 35.5 vs. 21.8 ± 28.5 g/day; P < .0001), and insulin delivery was significantly lower (31.5 ± 10.5 vs. 34.0 ± 10.5 U/day; P < .0001). The time spent in hyperglycaemia and the glycaemic variation coefficient increased significantly on days with PA. In real‐life conditions, the use of DBLG1 avoids PA‐induced hypoglycaemia. Insulin adjustments and preventive CHO recommendation may explain this therapeutic benefit.
- 19 May 2021
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (9) , 2170-2176
Open AccessNo more hypoglycaemia on days with physical activity and unrestricted diet when using a closed‐loop system for 12 weeks: A post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial
A post hoc analysis of the Diabeloop WP7 multicentre, randomized controlled trial was performed to investigate the efficacy of the Diabeloop Generation‐1 (DBLG1) closed‐loop system in controlling the hypoglycaemia induced by physical activity (PA) in real‐life conditions. Glycaemic outcomes were compared between days with and without PA in 56 patients with type 1 diabetes (T1D) using DBLG1 for 12 weeks. After the patient announces a PA, DBLG1 reduces insulin delivery and, if necessary, calculates the amount of preventive carbohydrates (CHO). Daily time spent in the interstitial glucose range less than 70 mg/dL was not significantly different between days with and without PA (2.0% ± 1.5% vs. 2.2% ± 1.1%), regardless of the intensity or duration of the PA. Preventive CHO intake recommended by the system was significantly higher in days with PA (41.1 ± 35.5 vs. 21.8 ± 28.5 g/day; P < .0001), and insulin delivery was significantly lower (31.5 ± 10.5 vs. 34.0 ± 10.5 U/day; P < .0001). The time spent in hyperglycaemia and the glycaemic variation coefficient increased significantly on days with PA. In real‐life conditions, the use of DBLG1 avoids PA‐induced hypoglycaemia. Insulin adjustments and preventive CHO recommendation may explain this therapeutic benefit.